Drugs / Meningitec
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 36 trials · 1 met primary | ||||||
| Phase 3 | NCT01506193 | Feb 2012 → Feb 2014 | chickenpox, measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00463437 | Apr 2007 → Jan 2008 | diphtheria, hepatitis B virus infection, pneumococcal infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00136604 | Jan → Apr 2006 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00317187 | Jun 2004 → Jan 2005 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00317135 | Dec 2003 → Oct 2004 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00352963 | Sep 2003 → Jul 2004 | diphtheria, hepatitis B virus infection, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00581035 | Jan 2006 → May 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00197808 | Apr 2005 → Jan 2010 | meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 2 | NCT00427908 Comparator | Feb → Dec 2007 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00126984 Comparator | Jul 2005 → Feb 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00134719 Comparator | Apr 2005 → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00196976 Comparator | Mar 2005 → Mar 2006 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00127855 Comparator | Mar 2003 → Feb 2004 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00801957 Background | Mar 2003 → Nov 2004 | atopic eczema | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00955682 Comparator | Aug → Dec 2009 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00508261 Comparator | Aug 2007 → May 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00474266 Comparator | Jun 2007 → Feb 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00326118 Comparator | Jun 2006 → Nov 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00322335 Comparator | May → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02526394 Comparator | Sep 2013 → Mar 2017 | meningococcal meningitis, pertussis | Public Health England | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningitec | “Meningitec at 2 and 3 months” NCT00197808 ↗ |
| Modality | Vaccine | “Meningitec™ or Mencevax™ ACWY vaccine will serve as active control.” NCT00126984 ↗ |
| Route | Intramuscular | “One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age” NCT00126984 ↗ |